Form 4 for AGIO AGIOS PHARMACEUTICALS, INC.
Accepted 2025-10-29 00:00:00 ET · period of report 2025-10-27 · accession 0001439222-25-000111 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-10-29 | 2025-10-27 | AGIO | Gheuens Sarah | Chief Medical Off | S - Sale+OE | $43.92 | -3,302 | 61.7K | -5% | -$145.0K |
| D | 2025-10-29 | 2025-10-27 | AGIO | Gheuens Sarah | Chief Medical Off | M - OptEx | $25.01 | +3,302 | 65.0K | +5% | +$82.6K |
| D | 2025-10-29 | 2025-10-27 | AGIO | Gheuens Sarah | Chief Medical Off | M - OptEx | $0.00 | -3,302 | 28.8K | -10% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock | 2025-10-27 | S | D | 3,302 | $43.92 | 61,727 | D | — | — | (F3) The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $43.77 to $44.13. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. |
| 2 | Common | Common stock | 2025-10-27 | M | A | 3,302 | $25.01 | 65,029 | D | — | — | (F1) Includes 456 shares purchased through the Company's employee stock purchase plan. |
| 3 | Derivative | Stock options (right to buy) | 2025-10-27 | M | D | 3,302 | $0.00 | 28,784 | D | $25.01 · — to 2033-03-01 | 3,302 Common stock | (F4) This option was originally granted on March 1, 2023 for the purchase of 44,000 shares of common stock. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter. |